Switch to:
Also traded in: Argentina, Austria, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.33
PFE's Cash-to-Debt is ranked lower than
75% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. PFE: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
PFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.78 Max: N/A
Current: 0.33
Equity-to-Asset 0.35
PFE's Equity-to-Asset is ranked lower than
85% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. PFE: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
PFE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.47 Max: 0.66
Current: 0.35
0.35
0.66
Interest Coverage 11.61
PFE's Interest Coverage is ranked lower than
71% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. PFE: 11.61 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.24  Med: 9.8 Max: 22.72
Current: 11.61
5.24
22.72
Piotroski F-Score: 6
Altman Z-Score: 2.30
Beneish M-Score: -2.59
WACC vs ROIC
7.63%
13.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 26.25
PFE's Operating Margin % is ranked higher than
89% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. PFE: 26.25 )
Ranked among companies with meaningful Operating Margin % only.
PFE' s Operating Margin % Range Over the Past 10 Years
Min: 13.89  Med: 23.4 Max: 32.43
Current: 26.25
13.89
32.43
Net Margin % 13.92
PFE's Net Margin % is ranked higher than
75% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. PFE: 13.92 )
Ranked among companies with meaningful Net Margin % only.
PFE' s Net Margin % Range Over the Past 10 Years
Min: 12.18  Med: 16.8 Max: 42.65
Current: 13.92
12.18
42.65
ROE % 11.92
PFE's ROE % is ranked higher than
67% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. PFE: 11.92 )
Ranked among companies with meaningful ROE % only.
PFE' s ROE % Range Over the Past 10 Years
Min: 9.29  Med: 11.86 Max: 27.93
Current: 11.92
9.29
27.93
ROA % 4.29
PFE's ROA % is ranked higher than
54% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. PFE: 4.29 )
Ranked among companies with meaningful ROA % only.
PFE' s ROA % Range Over the Past 10 Years
Min: 4.05  Med: 5.34 Max: 12.3
Current: 4.29
4.05
12.3
ROC (Joel Greenblatt) % 59.08
PFE's ROC (Joel Greenblatt) % is ranked higher than
86% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. PFE: 59.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 40.57  Med: 59.29 Max: 85.94
Current: 59.08
40.57
85.94
3-Year Revenue Growth Rate 4.70
PFE's 3-Year Revenue Growth Rate is ranked lower than
52% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. PFE: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PFE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 6.4 Max: 33.5
Current: 4.7
-7.1
33.5
3-Year EBITDA Growth Rate -10.10
PFE's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. PFE: -10.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PFE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1  Med: 4.8 Max: 42.6
Current: -10.1
-10.1
42.6
3-Year EPS without NRI Growth Rate -10.80
PFE's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. PFE: -10.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PFE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8  Med: 5.6 Max: 90.5
Current: -10.8
-26.8
90.5
GuruFocus has detected 4 Warning Signs with Pfizer Inc $PFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PFE's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PFE Guru Trades in Q3 2016

Jim Simons 8,566,241 sh (+390.79%)
Lee Ainslie 21,380,155 sh (+16.03%)
NWQ Managers 2,360,862 sh (+12.67%)
Ray Dalio 626,339 sh (+11.72%)
Richard Pzena 2,329,636 sh (+6.55%)
Diamond Hill Capital 11,856,263 sh (+1.80%)
Mairs and Power 4,555,073 sh (+1.62%)
Ken Fisher 31,836,368 sh (+0.35%)
David Dreman 29,962 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Eric Mindich 3,050,000 sh (unchged)
David Carlson 300,000 sh (unchged)
Ruane Cunniff Sold Out
Tom Russo Sold Out
T Rowe Price Equity Income Fund 13,875,000 sh (-0.48%)
Manning & Napier Advisors, Inc 645,026 sh (-0.92%)
Jeff Auxier 85,015 sh (-1.03%)
John Burbank 409,366 sh (-2.58%)
Ronald Muhlenkamp 36,034 sh (-2.74%)
Mario Gabelli 502,386 sh (-3.00%)
Murray Stahl 65,882 sh (-3.48%)
Barrow, Hanley, Mewhinney & Strauss 47,267,043 sh (-3.50%)
Charles Brandes 5,032,007 sh (-3.81%)
John Buckingham 72,763 sh (-3.82%)
Dodge & Cox 773,142 sh (-6.92%)
Keeley Asset Management Corp 91,630 sh (-8.92%)
Pioneer Investments 13,857,332 sh (-10.53%)
First Eagle Investment 66,061 sh (-13.15%)
Paul Tudor Jones 17,200 sh (-20.00%)
Kahn Brothers 919,757 sh (-20.50%)
Joel Greenblatt 1,158,937 sh (-40.21%)
Jeremy Grantham 6,716,818 sh (-45.31%)
John Paulson 252,000 sh (-50.63%)
» More
Q4 2016

PFE Guru Trades in Q4 2016

David Tepper 4,810,000 sh (New)
Steven Cohen 214,100 sh (New)
Eaton Vance Worldwide Health Sciences Fund 1,462,345 sh (New)
John Paulson 352,200 sh (+39.76%)
Diamond Hill Capital 12,957,027 sh (+9.28%)
Lee Ainslie 22,851,570 sh (+6.88%)
Manning & Napier Advisors, Inc 684,000 sh (+6.04%)
Murray Stahl 69,400 sh (+5.34%)
Charles Brandes 5,271,418 sh (+4.76%)
Mairs and Power 4,725,178 sh (+3.73%)
John Buckingham 74,141 sh (+1.89%)
Ken Fisher 32,204,753 sh (+1.16%)
Jeff Auxier 85,493 sh (+0.56%)
T Rowe Price Equity Income Fund 13,900,000 sh (+0.18%)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
David Carlson 300,000 sh (unchged)
John Burbank Sold Out
Mario Gabelli 490,448 sh (-2.38%)
Keeley Asset Management Corp 89,323 sh (-2.52%)
Dodge & Cox 746,972 sh (-3.38%)
NWQ Managers 2,280,229 sh (-3.42%)
Barrow, Hanley, Mewhinney & Strauss 45,401,940 sh (-3.95%)
Richard Pzena 2,217,509 sh (-4.81%)
Ronald Muhlenkamp 33,984 sh (-5.69%)
Kahn Brothers 860,290 sh (-6.47%)
Jeremy Grantham 5,451,421 sh (-18.84%)
Pioneer Investments 9,476,885 sh (-31.61%)
Joel Greenblatt 759,374 sh (-34.48%)
Paul Tudor Jones 10,900 sh (-36.63%)
David Dreman 18,901 sh (-36.92%)
Ray Dalio 282,200 sh (-54.94%)
Jim Simons 2,847,000 sh (-66.76%)
» More
Q1 2017

PFE Guru Trades in Q1 2017

George Soros 31,200 sh (New)
David Carlson 650,000 sh (+116.67%)
Joel Greenblatt 944,660 sh (+24.40%)
John Paulson 407,500 sh (+15.70%)
Charles Brandes 6,018,005 sh (+14.16%)
Manning & Napier Advisors, Inc 719,433 sh (+5.18%)
Mairs and Power 4,871,107 sh (+3.09%)
Ken Fisher 32,759,530 sh (+1.72%)
Murray Stahl 70,082 sh (+0.98%)
John Buckingham 74,585 sh (+0.60%)
David Dreman 18,901 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Richard Pzena 2,217,509 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Jeff Auxier 84,868 sh (-0.73%)
Mario Gabelli 485,466 sh (-1.02%)
Ronald Muhlenkamp 33,034 sh (-2.80%)
Diamond Hill Capital 12,358,068 sh (-4.62%)
Barrow, Hanley, Mewhinney & Strauss 42,835,523 sh (-5.65%)
Pioneer Investments 8,844,361 sh (-6.67%)
Dodge & Cox 678,070 sh (-9.22%)
T Rowe Price Equity Income Fund 12,325,000 sh (-11.33%)
Jeremy Grantham 4,786,189 sh (-12.20%)
Lee Ainslie 19,833,477 sh (-13.21%)
Kahn Brothers 667,633 sh (-22.39%)
David Tepper 3,021,000 sh (-37.19%)
Paul Tudor Jones 6,400 sh (-41.28%)
NWQ Managers 1,313,554 sh (-42.39%)
Ray Dalio 62,095 sh (-78.00%)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (-9.19%)
» More
Q2 2017

PFE Guru Trades in Q2 2017

Ken Fisher 34,035,362 sh (+3.89%)
T Rowe Price Equity Income Fund 10,237,000 sh (-16.94%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:MRK, NYSE:ABBV, NYSE:LLY, NYSE:BMY, NYSE:JNJ, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:RMTI, NAS:ZGNX, NAS:ALIM, AMEX:NNVC, NAS:PRPH, NAS:TNXP, NAS:IMNP, AMEX:AXN, OTCPK:INNV, NAS:ALQA, OTCPK:INBP, OTCPK:ECTE » details
Traded in other countries:PFE.Argentina, PFE.Austria, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, 0Q1N.UK,
Headquarter Location:USA
Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Prescription drugs and vaccines account for the majority of sales. Top sellers include vaccine Prevnar 13 against meningitis and Lyrica for epilepsy and some types of neuropathic pain. Pfizer sells these products globally with international sales representing over 50% of its total sales.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Pfizer Inc

Why Emmaus Might Have Just Made Itself Attractive to Big Pharma How the company's latest development makes it a potential takeover target
If you would have mentioned the name Emmaus Life Sciences to an investor, even one familiar with the biotechnology space, a couple of months ago, chances are the said investor would not have had any idea who you were talking about. In fact, the same probably applies today. Read more...
Stock Markets Mostly Flat Tuesday Morning Investors are waiting for several speeches by Fed officials
At a time when the three indices are down and Asian stocks rise as the dollar reached a two-month peak against the yen. The U.S. dollar index, which follows a basket of six currencies, is at 96.08. Meanwhile, a senior Federal Reserve official expects a further increase in interest rates and the central bank will begin to lower its huge balance in the coming months. Read more...
Wall Street Opens Without a Clear Direction The market expects more economic data and the appearance of Yellen before Congress
In a volatile morning session, the three major indices are now in the green while the U.S. economy continues to generate jobs and growth at a steady pace, with good data on consumer confidence and investment according to the Federal Reserve's semi-annual report. Although there are few indications of a liquidity crisis in the fixed-income market, there are not any problems with valuations of financial assets. Notwithstanding, the Fed highlighted some long-term problems stemming from weak productivity growth. Read more...
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
Investors: Option reports for Citigroup, The Gap, Nike, NVIDIA and Pfizer Inc. include trade ideas that offer returns of 18% or more!
Nasdaq Reports Another New High Dow Jones and S&P 500 report losses for the day
U.S. market indexes were mixed on Tuesday with the Nasdaq reporting another new high. Read more...
Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy
Covered Call reports for Apple, Coty Inc., NVIDIA, Pfizer Inc. and Yelp include trade ideas that offer returns of 21% or more!
Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy

Ratios

vs
industry
vs
history
PE Ratio 28.18
PFE's PE Ratio is ranked lower than
51% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. PFE: 28.18 )
Ranked among companies with meaningful PE Ratio only.
PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.68  Med: 16.53 Max: 34.77
Current: 28.18
7.68
34.77
Forward PE Ratio 13.18
PFE's Forward PE Ratio is ranked higher than
78% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. PFE: 13.18 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.94
PFE's PE Ratio without NRI is ranked lower than
51% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. PFE: 27.94 )
Ranked among companies with meaningful PE Ratio without NRI only.
PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.83  Med: 19.41 Max: 34.43
Current: 27.94
9.83
34.43
Price-to-Owner-Earnings 17.57
PFE's Price-to-Owner-Earnings is ranked higher than
75% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. PFE: 17.57 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.37  Med: 10.6 Max: 30.35
Current: 17.57
5.37
30.35
PB Ratio 3.42
PFE's PB Ratio is ranked lower than
59% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. PFE: 3.42 )
Ranked among companies with meaningful PB Ratio only.
PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.44 Max: 3.72
Current: 3.42
1.32
3.72
PS Ratio 3.91
PFE's PS Ratio is ranked lower than
60% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. PFE: 3.91 )
Ranked among companies with meaningful PS Ratio only.
PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.53 Max: 4.74
Current: 3.91
1.72
4.74
Price-to-Free-Cash-Flow 14.95
PFE's Price-to-Free-Cash-Flow is ranked higher than
73% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. PFE: 14.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 13.04 Max: 18.91
Current: 14.95
5.02
18.91
Price-to-Operating-Cash-Flow 13.00
PFE's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. PFE: 13.00 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.55  Med: 11.71 Max: 15.89
Current: 13
4.55
15.89
EV-to-EBIT 23.14
PFE's EV-to-EBIT is ranked lower than
57% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. PFE: 23.14 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.1 Max: 28.8
Current: 23.14
6.7
28.8
EV-to-EBITDA 14.55
PFE's EV-to-EBITDA is ranked higher than
58% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. PFE: 14.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.3 Max: 17.3
Current: 14.55
4.9
17.3
Shiller PE Ratio 21.17
PFE's Shiller PE Ratio is ranked higher than
79% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. PFE: 21.17 )
Ranked among companies with meaningful Shiller PE Ratio only.
PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.05  Med: 16.72 Max: 25.32
Current: 21.17
9.05
25.32
Current Ratio 1.44
PFE's Current Ratio is ranked lower than
74% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. PFE: 1.44 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.52 Max: 3.18
Current: 1.44
0.98
3.18
Quick Ratio 1.14
PFE's Quick Ratio is ranked lower than
71% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. PFE: 1.14 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.23 Max: 2.86
Current: 1.14
0.74
2.86
Days Inventory 225.46
PFE's Days Inventory is ranked lower than
86% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. PFE: 225.46 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 229.34 Max: 344.63
Current: 225.46
185.33
344.63
Days Sales Outstanding 61.70
PFE's Days Sales Outstanding is ranked higher than
62% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. PFE: 61.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.83  Med: 70.69 Max: 106.89
Current: 61.7
56.83
106.89
Days Payable 103.66
PFE's Days Payable is ranked higher than
70% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. PFE: 103.66 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 127.13 Max: 179.46
Current: 103.66
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.70
PFE's Dividend Yield % is ranked higher than
89% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. PFE: 3.70 )
Ranked among companies with meaningful Dividend Yield % only.
PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.9  Med: 3.7 Max: 10.4
Current: 3.7
2.9
10.4
Dividend Payout Ratio 1.03
PFE's Dividend Payout Ratio is ranked lower than
77% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. PFE: 1.03 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.77 Max: 1.08
Current: 1.03
0.58
1.08
3-Year Dividend Growth Rate 7.70
PFE's 3-Year Dividend Growth Rate is ranked higher than
53% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. PFE: 7.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 12.6 Max: 22.6
Current: 7.7
-14.7
22.6
Forward Dividend Yield % 3.81
PFE's Forward Dividend Yield % is ranked higher than
88% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 3.81 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.54
PFE's 5-Year Yield-on-Cost % is ranked higher than
89% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. PFE: 5.54 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.34  Med: 5.54 Max: 15.57
Current: 5.54
4.34
15.57
3-Year Average Share Buyback Ratio 1.70
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. PFE: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: 0.1 Max: 7.2
Current: 1.7
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.08
PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. PFE: 1.08 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.25 Max: 12.28
Current: 1.08
0.53
12.28
Price-to-Median-PS-Value 1.11
PFE's Price-to-Median-PS-Value is ranked higher than
50% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. PFE: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 1.05 Max: 4.3
Current: 1.11
0.43
4.3
Earnings Yield (Greenblatt) % 4.32
PFE's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. PFE: 4.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.5  Med: 7.1 Max: 14.9
Current: 4.32
3.5
14.9
Forward Rate of Return (Yacktman) % 1.51
PFE's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. PFE: 1.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.3  Med: 13.3 Max: 22.4
Current: 1.51
1.3
22.4

More Statistics

Revenue (TTM) (Mil) $52,599.00
EPS (TTM) $ 1.19
Beta1.07
Short Percentage of Float0.73%
52-Week Range $29.83 - 37.39
Shares Outstanding (Mil)5,967.84

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 52,911 54,051 53,088
EPS ($) 2.54 2.73 2.78
EPS without NRI ($) 2.54 2.73 2.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.01%
Dividends per Share ($) 1.29 1.37 1.45
» More Articles for PFE

Headlines

Articles On GuruFocus.com
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma Jul 14 2017 
Stock Markets Mostly Flat Tuesday Morning Jul 11 2017 
Wall Street Opens Without a Clear Direction Jul 10 2017 
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of en Jun 09 2017 
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Recei Jun 07 2017 
Portola Pharmaceuticals Could Be a Great June Trade Jun 02 2017 
Investors: Option reports for Citigroup, The Gap, Nike, NVIDIA and Pfizer Inc. include trade ideas t May 22 2017 
Nasdaq Reports Another New High May 16 2017 
Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Th May 16 2017 
Covered Call reports for Apple, Coty Inc., NVIDIA, Pfizer Inc. and Yelp include trade ideas that off May 11 2017 

More From Other Websites
Tesla Started At Neutral, High Risk; Amazon Gets Price Target Hike Jul 20 2017
Trump unveils companies' $500 million U.S. drug packaging project Jul 20 2017
Merck, Pfizer CEOs talk 'Made in America' week Jul 20 2017
Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Packaging Jul 20 2017
5 New Breast Cancer Treatments From Lilly, Novartis and Pfizer That Could Double Sales by 2021 Jul 20 2017
Pfizer Downgraded on Patent Expiration for Viagra: Credit Suisse Jul 20 2017
Analyst Prescribes Neutral Rating For Pfizer Shares Jul 20 2017
Pfizer: We Still Like You But… Jul 20 2017
Pfizer shares downgraded because Viagra patent is expiring later this year Jul 20 2017
Pfizer Completes License Agreement For The Exclusive Commercialization Rights In Europe For CRESEMBA... Jul 20 2017
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for... Jul 20 2017
Cramer's lightning round: GameStop just can't seem to go ... Jul 19 2017
Cramer's lightning round: GameStop just can't seem to go higher Jul 19 2017
4 Healthcare Megatrends for Investors Jul 19 2017
How Bayer Is Creating Value through Innovation Jul 17 2017
How to Identify Economic Moats Jul 17 2017
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter Jul 16 2017
Roundtable: 1 Stock I'm Never Selling Jul 16 2017
[$$] "A Great Time" to Invest in the Health-Care Sector Jul 14 2017
Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter Jul 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}